Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rom, William N ^a   Goldberg, Judith D ^a   Addrizzo Harris, Doreen ^a   Watson, Heather N ^a   Khilkin, Michael ^a   Greenberg, Alissa K ^a   Naidich, David P ^a   Crawford, Bernard ^a   Eylers, Ellen ^a   Liu, Daorong ^b   Tan, Eng M ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; MYC PROTEIN; SURVIVIN; TUMOR ANTIGEN;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CLASSIFICATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FORCED VITAL CAPACITY; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; SOLID TUMOR; AGED; BLOOD; COMPARATIVE STUDY; EARLY DIAGNOSIS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952646004     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-234     Document Type: Article

References (41)

1. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. International Early Lung Cancer Action Program Investigators Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-71. 10.1056/NEJMoa060476, 17065637, International Early Lung Cancer Action Program Investigators.
2. Mulshine JL, Sullivan D. Lung cancer screening. N Engl J Med 2005, 352:2714-20. 10.1056/NEJMcp042630, 15987920.
3. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354:99-105. 10.1016/S0140-6736(99)06093-6, 10408484.
4. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408. 10.1002/ijc.2910300404, 6292117.
5. Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clinical Cancer Research 1996, 2:1767-1775.
6. Sangrajrang S, Sornprom A, Chernrungroj G, Soussi T. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 2003, 39:297-301. 10.1016/S0169-5002(02)00509-3, 12609568.
7. Li Y, Brandt-Rauf PW, Carney WP, Tenney DY, Ford JD. Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers 1999, 4:381-390.
8. Diesinger I, Bauer C, Brass N, Schaefers HJ, Comtesse N, Sybrecht G, Meese E. Towards a more complete recognition of immunoreactive antigens in squamous cell lung adenocarcinoma. Int J Cancer 2002, 102:372-8. 10.1002/ijc.10714, 12402307.
9. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187:1349-54. 10.1084/jem.187.8.1349, 2212223, 9547346.
10. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993, 92:2419-2426. 10.1172/JCI116848, 288425, 8227358.
11. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998, 187:1163-7. 10.1084/jem.187.8.1163, 2212229, 9547328.
12. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108:1411-1415. 209427, 11714730.
13. Dalman J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Path 1992, 141:881-886. 1886624, 1415481.
14. Darnell RB. Onconeural antigens and the paraneoplastic disorders: at the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA 1996, 93:4529-4536. 10.1073/pnas.93.10.4529, 39311, 8643438.
15. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-7.
16. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997, 25:75-80. 10.1002/hep.510250114, 8985268.
17. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999, 45:162-7. 10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R, 9989617.
18. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thoracic Oncology 2006, 1:513-519.
19. Zhang JY, Chan EK, Peng XX, Lu M, Wang X, Mueller F, Tan EM. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001, 100:149-156. 10.1006/clim.2001.5048, 11465943.
20. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001, 98:9824-9829. 10.1073/pnas.171320598, 55537, 11504947.
21. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001, 61:7908-12.
22. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63:228-233. 10.1136/thx.2007.083592, 17932110.
23. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
24. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003, 9:5120-6.
25. Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T, Casiano CA, Heeb MJ, Chan EK, Tan E. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005, 63:252-258. 10.1002/pros.20181, 15538718.
26. Himoto T, Kuriyama S, Zhang JY, Chan EK, Kimura Y, Masaki T, Uchida N, Nishioka M, Tan EM. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 2005, 27:1079-1085.
27. Zhang JY, Chan EK, Peng XX, Tan EM. A novel protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999, 189:1101-1110. 10.1084/jem.189.7.1101, 2193003, 10190901.
28. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa "companion" auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21:5006-15. 10.1038/sj.onc.1205625, 12118381.
29. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002, 8:2298-2305.
30. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003, 100:13537-42. 10.1073/pnas.2233850100, 263849, 14573703.
31. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer. Cancer Res 2003, 63:1652-1656.
32. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004, 46:313-323. 10.1016/j.lungcan.2004.05.013, 15541816.
33. Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, Greenberg AK, Rom WN, Brenner DE, Omenn GS, Haab BB, Hanash SM. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005, 5:110. 10.1186/1471-2407-5-110, 1198221, 16117833.
34. Sin DD, Man SFP, McWilliams A, Lam S. Progression of airway dysplasia and C-Reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2006, 173:535-9. 10.1164/rccm.200508-1305OC, 2662937, 16339918.
35. Qiu J, Choi G, Lin L, Wang H, Pitteri S, Pereira-Faca S, Krasnoselsky A, Randolph T, Omenn G, Edelstein C, Barnett M, Thornquist M, Goodman G, Brenner D, Feng Z, Hanash S. Occurrence of autoantibodies to Annexin I, 14-3-3 Theta, and LAMR1 in prediagnostic lung cancer sera. J Clin Oncology 2008, 26:1-8.
36. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 2003, 27:285-90. 10.1016/S0361-090X(03)00097-7, 12893076.
37. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005, 172:1308-1314. 10.1164/rccm.200505-830OC, 2718416, 16109979.
38. Furukawa C, Daigo Y, Ishikawa N, Kato T, Ito T, Tsuchiya E, Sone S, Nakamura Y. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005, 65:7102-7110. 10.1158/0008-5472.CAN-04-1877, 16103059.
39. Chen G, Wang X, Yu J, Varambally S, Yu J, Thomas DG, Lin MY, Vishnu P, Wang Z, Wang R, Fielhauer J, Ghosh D, Giordano TJ, Giacherio D, Chang AC, Orringer MB, El-Hefnawy T, Bigbee WL, Beer DG, Chinnaiyan AM. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007, 67:3461-3467. 10.1158/0008-5472.CAN-06-4475, 17409457.
40. Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 2001, 21:3085-92.
41. Nakata M, Saeki H, Takata I, Segawa Y, Mogami H, Mandai K, Eguchi K. Focal ground-glass opacity detected by low-dose helical CT. Chest 2002, 121:1464-7. 10.1378/chest.121.5.1464, 12006429.